Search

• GSK and Theravance announce results from the SUMMIT COPD CV Survival Study

  Media

  GSK and THRX announced initial results from study for Relvar®Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’).

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-results-from-the-summit-copd-cv-survival-study/

  First published: 08 September 2015

• Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements

  Media

  Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe

  https://www.gsk.com/en-gb/media/press-releases/five-years-on-39-million-people-in-the-developing-world-have-access-to-hiv-treatment-dolutegravir-thanks-to-access-oriented-voluntary-licensing-agreements/

  First published: 30 July 2019

• Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance

  Media

  Governments and industry called on to work in parallel in taking comprehensive action against drug-resistant infections

  https://www.gsk.com/en-gb/media/press-releases/global-pharmaceutical-industry-calls-on-governments-to-work-with-them-to-beat-the-rising-threat-of-drug-resistance/

  First published: 21 January 2016

• GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older

  Media

  An approval from the US Food and Drug Administration’s (FDA) Center

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older/

  First published: 18 November 2016

• GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID

  Media

  Today announced the submission of a marketing application to the EMA for a gene therapy (GSK2696273) to treat patients with a rare disease

  https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/

  First published: 05 May 2015

• GSK announces start of phase III study of sirukumab in Giant Cell Arteritis

  Media

  GSK announced that dosing has commenced in a phase III study evaluating sirukumab.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/

  First published: 25 November 2015

• Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD

  Media

  GSK & THRX announced that CHMP of EMA has issued a positive opinion recommending marketing authorisation for UMEC/VI ,brand name Anoro®

  https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidinium-vilanterol-receives-positive-opinion-from-the-chmp-in-europe-for-the-treatment-of-copd/

  First published: 20 February 2014

• GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan

  Media

  GSK and THRX today announced the start of a Phase III efficacy and study of a combination treatment of the inhaled corticosteroid (ICS).

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-phase-iii-study-of-fluticasone-furoatevilanterol-in-copd-commenced-to-support-potential-future-filing-in-japan/

  First published: 22 April 2014

• Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD

  Media

  GSK & THRX announced that recruitment of patients into the study known as SUMMIT, has completed enrolment.

  https://www.gsk.com/en-gb/media/press-releases/patient-recruitment-completes-in-landmark-relvar-breo-ellipta-study-to-understand-mortality-and-morbidity-summit-in-copd/

  First published: 13 March 2014

• Ebola vaccine trials fast-tracked by international consortium

  Media

  Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine

  https://www.gsk.com/en-gb/media/press-releases/ebola-vaccine-trials-fast-tracked-by-international-consortium/

  First published: 28 August 2014